May the remodeling of the Ca2+ toolkit in endothelial progenitor cells derived from cancer patients suggest alternative targets for anti-angiogenic treatment?

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1853, Issue 9, 2015, Pages 1958-1973

  Moccia, Francesco ^a   Poletto, Valentina ^b  

^a Laboratory of General Physiology   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Endothelial progenitor cel; Orai1; Stim1; TRPC1; Tumor vascularization; Vascular endothelial growth facto

Indexed keywords

VASCULOTROPIN RECEPTOR 2; CALCIUM; CALCIUM CHANNEL; TUMOR PROTEIN;

ALTERNATIVE MEDICINE; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; BREAST CANCER; CALCIUM SIGNALING; CANCER PATIENT; CELL PROLIFERATION; CUTANEOUS MELANOMA; DOWN REGULATION; ENDOPLASMIC RETICULUM; ENDOTHELIAL PROGENITOR CELL; GENE EXPRESSION; HUMAN; KIDNEY CARCINOMA; LUNG ADENOCARCINOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEM CELL MOBILIZATION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ANIMAL; ENDOTHELIUM CELL; METABOLISM; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; STEM CELL; VASCULARIZATION;

ANIMALS; CALCIUM; CALCIUM CHANNELS; CALCIUM SIGNALING; ENDOTHELIAL CELLS; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; STEM CELLS;

EID: 84943403628     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2014.10.024     Document Type: Review

References (193)

1. Berridge M.J., Bootman M.D., Roderick H.L. Calcium signalling: dynamics, homeostasis and remodelling. Nat. Rev. Mol. Cell Biol. 2003, 4:517-529.
2. Clapham D.E. Calcium signaling. Cell 2007, 131:1047-1058.
3. Santella L., Lim D., Moccia F. Calcium and fertilization: the beginning of life. Trends Biochem. Sci. 2004, 29:400-408.
4. Altaany Z., Moccia F., Munaron L., Mancardi D., Wang R. Hydrogen sulfide and endothelial dysfunction: relationship with nitric oxide. Curr. Med. Chem. 2014, 21:3646-3661.
5. Moccia F., Tanzi F., Munaron L. Endothelial remodelling and intracellular calcium machinery. Curr. Mol. Med. 2014, 14:457-480.
6. Berridge M.J. Dysregulation of neural calcium signaling in Alzheimer disease, bipolar disorder and schizophrenia. Prion 2013, 7:2-13.
7. Berridge M.J. Calcium signalling remodelling and disease. Biochem. Soc. Trans. 2012, 40:297-309.
8. 2+ transport. Nat. Rev. Cancer 2007, 7:519-530.
9. Prevarskaya N., Skryma R., Shuba Y. Calcium in tumour metastasis: new roles for known actors. Nat. Rev. Cancer 2011, 11:609-618.
10. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
11. 2+ signalling: a tale of ion channels, pumps and transporters. World J. Biol. Chem. 2012, 3:127-158.
12. 2+ waves: a novel target for cell-based therapy and anti-cancer treatment?. Curr. Signal Transduct. Ther. 2012, 7:161-176.
13. 2+ concentration. Stem Cells 2011, 29:1898-1907.
14. 2+ oscillations in endothelial progenitor cells isolated from umbilical cord blood. Stem Cells Dev. 2013, 22:2561-2580.
15. 2+ signalling in endothelial progenitor cells: a novel means to improve cell-based therapy and impair tumour vascularisation. Curr. Vasc. Pharmacol. 2014, 12:87-105.
16. De Bock K., Mazzone M., Carmeliet P. Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?. Nat. Rev. Clin. Oncol. 2011, 8:393-404.
17. Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473:298-307.
18. Peinado H., Lavotshkin S., Lyden D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin. Cancer Biol. 2011, 21:139-146.
19. Dudley A.C. Tumor endothelial cells. Cold Spring Harb. Perspect. Med. 2012, 2:a006536.
20. Moccia F., Dragoni S., Poletto V., Rosti V., Tanzi F., Ganini C., Porta C. Orai1 and Transient Receptor Potential channels as novel molecular targets to impair tumor neovascularisation in renal cell carcinoma and other malignancies. Anti Cancer Agents Med. Chem. 2014, 14:296-312.
21. Aird W.C. Endothelial cell heterogeneity. Cold Spring Harb. Perspect. Med. 2012, 2:a006429.
22. Gao D.C., Nolan D., McDonnell K., Vahdat L., Benezra R., Altorki N., Mittal V. Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression. Biochim. Biophys. Acta 2009, 1796:33-40.
23. Nolan D.J., Ciarrocchi A., Mellick A.S., Jaggi J.S., Bambino K., Gupta S., Heikamp E., McDevitt M.R., Scheinberg D.A., Benezra R., Mittal V. Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev. 2007, 21:1546-1558.
24. Munaron L., Genova T., Avanzato D., Antoniotti S., Fiorio Pla A. Targeting calcium channels to block tumor vascularization. Recent Pat. Anticancer Drug Discov. 2013, 8:27-37.
25. Fiorio Pla A., Gkika D. Emerging role of TRP channels in cell migration: from tumor vascularization to metastasis. Front. Physiol. 2013, 4:311.
26. 2+ entry in endothelial progenitor cells as a perspective tool to enhance cell-based therapy and adverse tumour vascularization. Curr. Med. Chem. 2012, 19:5802-5818.
27. Coghlin C., Murray G.I. Current and emerging concepts in tumour metastasis. J. Pathol. 2010, 222:1-15.
28. Patenaude A., Parker J., Karsan A. Involvement of endothelial progenitor cells in tumor vascularization. Microvasc. Res. 2010, 79:217-223.
29. Hill P.A. Recipient origin of vasculature in renal cell carcinoma in a kidney allograft. Pathology 2010, 42:479-480.
30. Peters B.A., Diaz L.A., Polyak K., Meszler L., Romans K., Guinan E.C., Antin J.H., Myerson D., Hamilton S.R., Vogelstein B., Kinzler K.W., Lengauer C. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat. Med. 2005, 11:261-262.
31. Lyden D., Hattori K., Dias S., Costa C., Blaikie P., Butros L., Chadburn A., Heissig B., Marks W., Witte L., Wu Y., Hicklin D., Zhu Z., Hackett N.R., Crystal R.G., Moore M.A., Hajjar K.A., Manova K., Benezra R., Rafii S. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 2001, 7:1194-1201.
32. Gao D.C., Nolan D.J., Mellick A.S., Bambino K., McDonnell K., Mittal V. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 2008, 319:195-198.
33. Mellick A.S., Plummer P.N., Nolan D.J., Gao D., Bambino K., Hahn M., Catena R., Turner V., McDonnell K., Benezra R., Brink R., Swarbrick A., Mittal V. Using the transcription factor inhibitor of DNA binding 1 to selectively target endothelial progenitor cells offers novel strategies to inhibit tumor angiogenesis and growth. Cancer Res. 2010, 70:7273-7282.
34. Plummer P.N., Freeman R., Taft R.J., Vider J., Sax M., Umer B.A., Gao D., Johns C., Mattick J.S., Wilton S.D., Ferro V., McMillan N.A., Swarbrick A., Mittal V., Mellick A.S. MicroRNAs regulate tumor angiogenesis modulated by endothelial progenitor cells. Cancer Res. 2013, 73:341-352.
35. Ruzinova M.B., Schoer R.A., Gerald W., Egan J.E., Pandolfi P.P., Rafii S., Manova K., Mittal V., Benezra R. Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell 2003, 4:277-289.
36. Yoder M.C. Human endothelial progenitor cells. Cold Spring Harb. Perspect. Med. 2012, 2:a006692.
37. Basile D.P., Yoder M.C. Circulating and tissue resident endothelial progenitor cells. J. Cell. Physiol. 2014, 229:10-16.
38. Asahara T., Kawamoto A., Masuda H. Concise review: circulating endothelial progenitor cells for vascular medicine. Stem Cells 2011, 29:1650-1655.
39. Medina R.J., O'Neill C.L., Sweeney M., Guduric-Fuchs J., Gardiner T.A., Simpson D.A., Stitt A.W. Molecular analysis of endothelial progenitor cell (EPC) subtypes reveals two distinct cell populations with different identities. BMC Med. Genomics 2010, 3:18.
40. Bieback K., Vinci M., Elvers-Hornung S., Bartol A., Gloe T., Czabanka M., Klüter H., Augustin H., Vajkoczy P. Recruitment of human cord blood-derived endothelial colony-forming cells to sites of tumor angiogenesis. Cytotherapy 2013, 15:726-739.
41. Smadja D.M., d'Audigier C., Weiswald L.B., Badoual C., Dangles-Marie V., Mauge L., Evrard S., Laurendeau I., Lallemand F., Germain S., Grelac F., Dizier B., Vidaud M., Bièche I., Gaussem P. The Wnt antagonist Dickkopf-1 increases endothelial progenitor cell angiogenic potential. Arterioscler. Thromb. Vasc. Biol. 2010, 30:2544-2552.
42. Wei J., Jarmy G., Genuneit J., Debatin K.M., Beltinger C. Human blood late outgrowth endothelial cells for gene therapy of cancer: determinants of efficacy. Gene Ther. 2007, 14:344-356.
43. Potente M., Gerhardt H., Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell 2011, 146:873-887.
44. Shaked Y., Henke E., Roodhart J.M., Mancuso P., Langenberg M.H., Colleoni M., Daenen L.G., Man S., Xu P., Emmenegger U., Tang T., Zhu Z., Witte L., Strieter R.M., Bertolini F., Voest E.E., Benezra R., Kerbel R.S. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008, 14:263-273.
45. Shaked Y., Ciarrocchi A., Franco M., Lee C.R., Man S., Cheung A.M., Hicklin D.J., Chaplin D., Foster F.S., Benezra R., Kerbel R.S. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006, 313:1785-1787.
46. Taylor M., Billiot F., Marty V., Rouffiac V., Cohen P., Tournay E., Opolon P., Louache F., Vassal G., Laplace-Builhé C., Vielh P., Soria J.C., Farace F. Reversing resistance to vascular-disrupting agents by blocking late mobilization of circulating endothelial progenitor cells. Cancer Discov. 2012, 2:434-449.
47. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 2008, 8:592-603.
48. Vasudev N.S., Reynolds A.R. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis 2014, 17:471-494.
49. Bertolini F., Marighetti P., Martin-Padura I., Mancuso P., Hu-Lowe D.D., Shaked Y., D'Onofrio A. Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer. Drug Discov. Today 2011, 16:1052-1060.
50. Ellis L.M., Hicklin D.J. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin. Cancer Res. 2008, 14:6371-6375.
51. Turtoi A., Mottet D., Matheus N., Dumont B., Peixoto P., Hennequière V., Deroanne C., Colige A., De Pauw E., Bellahcène A., Castronovo V. The angiogenesis suppressor gene AKAP12 is under the epigenetic control of HDAC7 in endothelial cells. Angiogenesis 2012, 15:543-554.
52. Song Y., Li X., Wang D., Fu C., Zhu Z., Zou M.H., Zhu Y. Transcription factor Krüppel-like factor 2 plays a vital role in endothelial colony forming cells differentiation. Cardiovasc. Res. 2013, 99:514-524.
53. Yu D., Chen W., Ren J., Zhang T., Yang K., Wu G., Liu H. VEGF-PKD1-HDAC7 signaling promotes endothelial progenitor cell migration and tube formation. Microvasc. Res. 2014, 91:66-72.
54. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat. Med. 2003, 9:669-676.
55. Koch S., Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb. Perspect. Med. 2012, 2:a006502.
56. Abdullaev I.F., Bisaillon J.M., Potier M., Gonzalez J.C., Motiani R.K., Trebak M. Stim1 and Orai1 mediate CRAC currents and store-operated calcium entry important for endothelial cell proliferation. Circ. Res. 2008, 103:1289-1299.
57. 2+ entry and endothelial tube formation. Circ. Res. 2011, 108:1190-1198.
58. Yu P.C., Gu S.Y., Bu J.W., Du J.L. TRPC1 is essential for in vivo angiogenesis in zebrafish. Circ. Res. 2010, 106:1221-1232.
59. Chen Y.-F., Chiu W.-T., Chen Y.-T., Lin P.-Y., Huang H.-J., Chou C.-Y., Chang H.-C., Tang M.-J., Shen M.-R. Calcium store sensor stromal-interaction molecule 1-dependent signaling plays an important role in cervical cancer growth, migration, and angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:15225-15230.
60. Pupo E., Pla A.F., Avanzato D., Moccia F., Cruz J.-E.A., Tanzi F., Merlino A., Mancardi D., Munaron L. Hydrogen sulfide promotes calcium signals and migration in tumor-derived endothelial cells. Free Radic. Biol. Med. 2011, 51:1765-1773.
61. 2+/calcineurin and protein kinase C-delta. PLoS One 2010, 5:e11435.
62. Rinne A., Banach K., Blatter L.A. Regulation of nuclear factor of activated T cells (NFAT) in vascular endothelial cells. J. Mol. Cell. Cardiol. 2009, 47:400-410.
63. 2+-dependent nitric oxide release in the injured endothelium of excised rat aorta: a promising mechanism applying in vascular prosthetic devices in aging patients. BMC Surg. 2013, 13(Suppl. 2):S40.
64. 2+ signaling, TRP channels, and endothelial permeability. Microcirculation 2006, 13:693-708.
65. -/- mice. Nat. Cell Biol. 2001, 3:121-127.
66. Cioffi D.L., Wu S., Chen H., Alexeyev M., St Croix C.M., Pitt B.R., Uhlig S., Stevens T. Orai1 determines calcium selectivity of an endogenous TRPC heterotetramer channel. Circ. Res. 2012, 110:1435-1444.
67. 2+ entry function of transient receptor potential canonical (TRPC) 1 and 4 channels in endothelial cells. Mol. Pharmacol. 2012, 81:510-526.
68. Munaron L., Fiorio Pla A. Calcium influx induced by activation of tyrosine kinase receptors in cultured bovine aortic endothelial cells. J. Cell. Physiol. 2000, 185:454-463.
69. Antoniotti S., Pla A.F., Pregnolato S., Mottola A., Lovisolo D., Munaron L. Control of endothelial cell proliferation by calcium influx and arachidonic acid metabolism: a pharmacological approach. J. Cell. Physiol. 2003, 197:370-378.
70. Pla A.F., Ong H.L., Cheng K.T., Brossa A., Bussolati B., Lockwich T., Paria B., Munaron L., Ambudkar I.S. TRPV4 mediates tumor-derived endothelial cell migration via arachidonic acid-activated actin remodeling. Oncogene 2012, 31:200-212.
71. Troidl C., Troidl K., Schierling W., Cai W.-J., Nef H., Moellmann H., Kostin S., Schimanski S., Hammer L., Elsaesser A., Schmitz-Rixen T., Schaper W. Trpv4 induces collateral vessel growth during regeneration of the arterial circulation. J. Cell. Mol. Med. 2009, 13:2613-2621.
72. Troidl C., Nef H., Voss S., Schilp A., Kostin S., Troidl K., Szardien S., Rolf A., Schmitz-Rixen T., Schaper W., Hamm C.W., Elsaesser A., Moellmann H. Calcium-dependent signalling is essential during collateral growth in the pig hind limb-ischemia model. J. Mol. Cell. Cardiol. 2010, 49:142-151.
73. 2+ oscillations in microvascular endothelial cells. J. Cell. Physiol. 2003, 194:139-150.
74. Ridefelt P., Yokote K., Claesson-Welsh L., Siegbahn A. PDGF-BB triggered cytoplasmic calcium responses in cells with endogenous or stably transfected PDGF beta-receptors. Growth Factors 1995, 12:191-201.
75. Bisaillon J.M., Motiani R.K., Gonzalez-Cobos J.C., Potier M., Halligan K.E., Alzawahra W.F., Barroso M., Singer H.A., Jourd'heuil D., Trebak M. Essential role for STIM1/Orai1-mediated calcium influx in PDGF-induced smooth muscle migration. Am. J. Physiol. Cell Physiol. 2010, 298:C993-C1005.
76. Pal S., Wu J., Murray J.K., Gellman S.H., Wozniak M.A., Keely P.J., Boyer M.E., Gomez T.M., Hasso S.M., Fallon J.F., Bresnick E.H. An antiangiogenic neurokinin-B/thromboxane A2 regulatory axis. J. Cell Biol. 2006, 174:1047-1058.
77. 2+ oscillations in human cerebrovascular endothelial cells after subarachnoid hemorrhage. J. Cereb. Blood Flow Metab. 2009, 29:57-65.
78. Berra-Romani R., Raqeeb A., Torres-Jácome J., Guzman-Silva A., Guerra G., Tanzi F., Moccia F. The mechanism of injury-induced intracellular calcium concentration oscillations in the endothelium of excised rat aorta. J. Vasc. Res. 2012, 49:65-76.
79. De Bock M., Culot M., Wang N., Bol M., Decrock E., De Vuyst E., da Costa A., Dauwe I., Vinken M., Simon A.M., Rogiers V., De Ley G., Evans W.H., Bultynck G., Dupont G., Cecchelli R., Leybaert L. Connexin channels provide a target to manipulate brain endothelial calcium dynamics and blood-brain barrier permeability. J. Cereb. Blood Flow Metab. 2011, 31:1942-1957.
80. 2+ oscillation frequency-regulated NF kappa B transcriptional activity. J. Cell Sci. 2011, 124:2591-2601.
81. 2+ oscillation frequency regulates agonist-stimulated gene expression in vascular endothelial cells. J. Cell Sci. 2008, 121:2511-2518.
82. Seidel J., Niggemann B., Punzel M., Fischer J., Zänker K.S., Dittmar T. The neurotransmitter GABA is a potent inhibitor of the stromal cell-derived factor-1alpha induced migration of adult CD133+ hematopoietic stem and progenitor cells. Stem Cells Dev. 2007, 16:827-836.
83. Ingram D.A., Mead L.E., Tanaka H., Meade V., Fenoglio A., Mortell K., Pollok K., Ferkowicz M.J., Gilley D., Yoder M.C. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood 2004, 104:2752-2760.
84. 2+ signals in human endothelial cells but not in their immature progenitors. Cell Calcium 2014, 56:225-234.
85. Skupin A., Falcke M. Statistical properties and information content of calcium oscillations. Genome Inform. 2007, 18:44-53.
86. 2+ oscillate: by chance or by the clock?. Biophys. J. 2008, 94:2404-2411.
87. Mac Gabhann F., Yang M.T., Popel A.S. Monte Carlo simulations of VEGF binding to cell surface receptors in vitro. Biochim. Biophys. Acta 2005, 1746:95-107.
88. 2+ signals. Biochim. Biophys. Acta 2012, 1820:1185-1194.
89. 2+ entry is expressed in human endothelial progenitor cells. Stem Cells Dev. 2010, 19:1967-1981.
90. 2+ concentration in endothelial cells from excised rat aorta. Curr. Pharm. Biotechnol. 2011, 12:1416-1426.
91. Munaron L., Avanzato D., Moccia F., Mancardi D. Hydrogen sulfide as a regulator of calcium channels. Cell Calcium 2013, 53:77-84.
92. 2+-permeable cationic channels in LNCaP human prostate cancer epithelial cells. J. Physiol. 2003, 548:823-836.
93. 2+ entry is remodelled and controls in vitro angiogenesis in endothelial progenitor cells isolated from tumoral patients. PLoS One 2012, 7:e42541.
94. Di Buduo C.A., Moccia F., Battiston M., De Marco L., Mazzucato M., Moratti R., Tanzi F., Balduini A. The importance of calcium in the regulation of megakaryocyte function. Haematologica 2014, 99:769-778.
95. Ong H.L., Cheng K.T., Liu X., Bandyopadhyay B.C., Paria B.C., Soboloff J., Pani B., Gwack Y., Srikanth S., Singh B.B., Gill D.L., Ambudkar I.S. Dynamic assembly of TRPC1-STIM1-Orai1 ternary complex is involved in store-operated calcium influx. Evidence for similarities in store-operated and calcium release-activated calcium channel components. J. Biol. Chem. 2007, 282:9105-9116.
96. Hoffmann A., Natoli G., Ghosh G. Transcriptional regulation via the NF-kappaB signaling module. Oncogene 2006, 25:6706-6716.
97. Minami T., Aird W.C. Endothelial cell gene regulation. Trends Cardiovasc. Med. 2005, 15:174-184.
98. 2+-operated transcriptional networks: molecular mechanisms and in vivo models. Physiol. Rev. 2008, 88:421-449.
99. Su Y., Gao L., Teng L., Wang Y., Cui J., Peng S., Fu S. Id1 enhances human ovarian cancer endothelial progenitor cell angiogenesis via PI3K/Akt and NF-κB/MMP-2 signaling pathways. J. Transl. Med. 2013, 11:132.
100. Li W., Wang H., Kuang C.Y., Zhu J.K., Yu Y., Qin Z.X., Liu J., Huang L. An essential role for the Id1/PI3K/Akt/NFkB/survivin signalling pathway in promoting the proliferation of endothelial progenitor cells in vitro. Mol. Cell. Biochem. 2012, 363:135-145.
101. Smedler E., Uhlén P. Frequency decoding of calcium oscillations. Biochim. Biophys. Acta 2014, 1840:964-969.
102. Skupin A., Kettenmann H., Falcke M. Calcium signals driven by single channel noise. PLoS Comput. Biol. 2010, 6.
103. 2+ influx through CRAC channels activates temporally and spatially distinct cellular responses. Acta Physiol. (Oxf) 2009, 195:29-35.
104. 2+ for cancer cell proliferation and survival. Nat. Rev. Cancer 2008, 8:361-375.
105. Nielsen N., Lindemann O., Schwab A. TRP channels and STIM/ORAI proteins: sensors and effectors of cancer and stroma cell migration. Br. J. Pharmacol. 2014, (Epub ahead of prinnt). 10.1111/bph.12721.
106. Dong Y., Pan Q., Jiang L., Chen Z., Zhang F., Liu Y., Xing H., Shi M., Li J., Li X., Zhu Y., Chen Y., Bruce I.C., Jin J., Ma X. Tumor endothelial expression of P-glycoprotein upon microvesicular transfer of TrpC5 derived from adriamycin-resistant breast cancer cells. Biochem. Biophys. Res. Commun. 2014, 446:85-90.
107. Barosi G., Lupo L., Rosti V. Management of myeloproliferative neoplasms: from academic guidelines to clinical practice. Curr. Hematol. Malig. Rep. 2012, 7:50-56.
108. Dragoni S., Laforenza U., Bonetti E., Reforgiato M., Poletto V., Lodola F., Bottino C., Guido D., Rappa A., Pareek S., Tomasello M., Guarrera M.R., Cinelli M.P., Aronica A., Guerra G., Barosi G., Tanzi F., Rosti V., Moccia F. Enhanced expression of Stim, Orai, and TRPC transcripts and proteins in endothelial progenitor cells isolated from patients with primary myelofibrosis. PLoS One 2014, 9:e91099.
109. Jaffe L.F. A calcium-based theory of carcinogenesis. Adv. Cancer Res. 2005, 94:231-263.
110. Borowiec A.S., Bidaux G., Tacine R., Dubar P., Pigat N., Delcourt P., Mignen O., Capiod T. Are Orai1 and Orai3 channels more important than calcium influx for cell proliferation?. Biochim. Biophys. Acta 2014, 1843:464-472.
111. Bhatt R.S., Zurita A.J., O'Neill A., Norden-Zfoni A., Zhang L., Wu H.K., Wen P.Y., George D., Sukhatme V.P., Atkins M.B., Heymach J.V. Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma. Br. J. Cancer 2011, 105:112-117.
112. Yang B., Gu W., Peng B., Xu Y., Liu M., Che J., Geng J., Zheng J. High level of circulating endothelial progenitor cells positively correlates with serum vascular endothelial growth factor in patients with renal cell carcinoma. J. Urol. 2012, 188:2055-2061.
113. Hernandez-Yanez M., Heymach J.V., Zurita A.J. Circulating biomarkers in advanced renal cell carcinoma: clinical applications. Curr. Oncol. Rep. 2012, 14:221-229.
114. Matsuda K., Ohga N., Hida Y., Muraki C., Tsuchiya K., Kurosu T., Akino T., Shih S.-C., Totsuka Y., Klagsbrun M., Shindoh M., Hida K. Isolated tumor endothelial cells maintain specific character during long-term culture. Biochem. Biophys. Res. Commun. 2010, 394:947-954.
115. Akino T., Hida K., Hida Y., Tsuchiya K., Freedman D., Muraki C., Ohga N., Matsuda K., Akiyama K., Harabayashi T., Shinohara N., Nonomura K., Klagsbrun M., Shindoh M. Cytogenetic abnormalities of tumor-associated endothelial cells in human malignant tumors. Am. J. Pathol. 2009, 175:2657-2667.
116. Escudier B., Szczylik C., Porta C., Gore M. Treatment selection in metastatic renal cell carcinoma: expert consensus. Nat. Rev. Clin. Oncol. 2012, 9:327-337.
117. Bussolati B., Deambrosis I., Russo S., Deregibus M.C., Camussi G. Altered angiogenesis and survival in human tumor-derived endothelial cells. FASEB J. 2003, 17:1159-1161.
118. Song J., Wang Y., Li X., Shen Y., Yin M., Guo Y., Diao L., Liu Y., Yue D. Critical role of TRPC6 channels in the development of human renal cell carcinoma. Mol. Biol. Rep. 2013, 40:5115-5122.
119. Kim J.H., Lkhagvadorj S., Lee M.R., Hwang K.H., Chung H.C., Jung J.H., Cha S.K., Eom M. Orai1 and STIM1 are critical for cell migration and proliferation of clear cell renal cell carcinoma. Biochem. Biophys. Res. Commun. 2014, 448:76-82.
120. Veliceasa D., Ivanovic M., Hoepfner F.T., Thumbikat P., Volpert O.V., Smith N.D. Transient potential receptor channel 4 controls thrombospondin-1 secretion and angiogenesis in renal cell carcinoma. FEBS J. 2007, 274:6365-6377.
121. 2+ regulation during neuronal differentiation of murine embryonal carcinoma and mesenchymal stem cells. Stem Cells Dev. 2010, 19:379-394.
122. Resende R.R., Adhikari A., da Costa J.L., Lorençon E., Ladeira M.S., Guatimosim S., Kihara A.H., Ladeira L.O. Influence of spontaneous calcium events on cell-cycle progression in embryonal carcinoma and adult stem cells. Biochim. Biophys. Acta 2010, 1803:246-260.
123. Lehen'kyi V.y., Shapovalov G., Skryma R., Prevarskaya N. Ion channnels and transporters in cancer. 5. Ion channels in control of cancer and cell apoptosis. Am. J. Physiol. Cell Physiol. 2011, 301:C1281-C1289.
124. 2+ homeostasis in apoptotic resistance of prostate cancer cells. Biochem. Biophys. Res. Commun. 2004, 322:1326-1335.
125. Patron M., Raffaello A., Granatiero V., Tosatto A., Merli G., De Stefani D., Wright L., Pallafacchina G., Terrin A., Mammucari C., Rizzuto R. The mitochondrial calcium uniporter (MCU): molecular identity and physiological roles. J. Biol. Chem. 2013, 288:10750-10758.
126. Gibalová L., Sedlák J., Labudová M., Barancík M., Reháková A., Breier A., Sulová Z. Multidrug resistant P-glycoprotein positive L1210/VCR cells are also cross-resistant to cisplatin via a mechanism distinct from P-glycoprotein-mediated drug efflux activity. Gen. Physiol. Biophys. 2009, 28:391-403.
127. Liao C.H., Hsiao Y.M., Sheu G.T., Chang J.T., Wang P.H., Wu M.F., Shieh G.J., Hsu C.P., Ko J.L. Nuclear translocation of telomerase reverse transcriptase and calcium signaling in repression of telomerase activity in human lung cancer cells by fungal immunomodulatory protein from Ganoderma tsugae. Biochem. Pharmacol. 2007, 74:1541-1554.
128. Rosenberger S., Thorey I.S., Werner S., Boukamp P. A novel regulator of telomerase. S100A8 mediates differentiation-dependent and calcium-induced inhibition of telomerase activity in the human epidermal keratinocyte line HaCaT. J. Biol. Chem. 2007, 282:6126-6135.
129. 2+-homeostasis is altered in small and non-small cell lung cancer cell lines. J. Exp. Clin. Cancer Res. 2009, 28:25.
130. 2+-ATPase in rat microvascular endothelial cells. Biochem. J. 2002, 364:235-244.
131. 2+ signaling in cancer cells: proto-oncogenes and tumor suppressors targeting IP3 receptors. Biochim. Biophys. Acta 2013, 1835:180-193.
132. 2+ levels in colorectal cancer cell lines. J. Cell Sci. 2014, 127:1607-1619.
133. Ivanova H., Vervliet T., Missiaen L., Parys J.B., De Smedt H., Bultynck G. Inositol 1,4,5-trisphosphate receptor-isoform diversity in cell death and survival. Biochim. Biophys. Acta 2014, 1843:2164-2183.
134. Chen Y.F., Chen Y.T., Chiu W.T., Shen M.R. Remodeling of calcium signaling in tumor progression. J. Biomed. Sci. 2013, 20:23.
135. Monteith G.R., Davis F.M., Roberts-Thomson S.J. Calcium channels and pumps in cancer: changes and consequences. J. Biol. Chem. 2012, 287:31666-31673.
136. Motiani R.K., Hyzinski-Garcia M.C., Zhang X., Henkel M.M., Abdullaev I.F., Kuo Y.-H., Matrougui K., Mongin A.A., Trebak M. STIM1 and Orai1 mediate CRAC channel activity and are essential for human glioblastoma invasion. Pflugers Arch. 2013, 465:1249-1260.
137. 2+ channel that promotes tumorigenesis. FASEB J. 2013, 27:63-75.
138. Stanisz H., Saul S., Müller C.S., Kappl R., Niemeyer B.A., Vogt T., Hoth M., Roesch A., Bogeski I. Inverse regulation of melanoma growth and migration by Orai1/STIM2-dependent calcium entry. Pigment Cell Melanoma Res. 2014, 27:442-453.
139. Mincheva-Tasheva S., Soler R.M. NF-κB signaling pathways: role in nervous system physiology and pathology. Neuroscientist 2013, 19:175-194.
140. Hoesel B., Schmid J.A. The complexity of NF-κB signaling in inflammation and cancer. Mol. Cancer 2013, 12:86.
141. Berridge M.J. The endoplasmic reticulum: a multifunctional signaling organelle. Cell Calcium 2002, 32:235-249.
142. Li J.L., Sainson R.C., Oon C.E., Turley H., Leek R., Sheldon H., Bridges E., Shi W., Snell C., Bowden E.T., Wu H., Chowdhury P.S., Russell A.J., Montgomery C.P., Poulsom R., Harris A.L. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res. 2011, 71:6073-6083.
143. Hou M.F., Kuo H.C., Li J.H., Wang Y.S., Chang C.C., Chen K.C., Chen W.C., Chiu C.C., Yang S., Chang W.C. Orai1/CRACM1 overexpression suppresses cell proliferation via attenuation of the store-operated calcium influx-mediated signalling pathway in A549 lung cancer cells. Biochim. Biophys. Acta 2011, 1810:1278-1284.
144. Wang J.Y., Chen B.K., Wang Y.S., Tsai Y.T., Chen W.C., Chang W.C., Hou M.F., Wu Y.C. Involvement of store-operated calcium signaling in EGF-mediated COX-2 gene activation in cancer cells. Cell. Signal. 2012, 24:162-169.
145. 2+ entry suppresses EGF-induced migration and eliminates extravasation from vasculature in nasopharyngeal carcinoma cell. Cancer Lett. 2013, 336:390-397.
146. 2+ oscillations in human esophageal squamous cell carcinoma. Oncotarget 2014, 5:3455-3471.
147. 2+ influx in MDA-MB-468 breast cancer cells and the effect of EGF-induced EMT on calcium entry. PLoS One 2012, 7:e36923.
148. Ouadid-Ahidouch H., Dhennin-Duthille I., Gautier M., Sevestre H., Ahidouch A. TRP channels: diagnostic markers and therapeutic targets for breast cancer?. Trends Mol. Med. 2013, 19:117-124.
149. Bomben V.C., Turner K.L., Barclay T.T.C., Sontheimer H. Transient Receptor Potential Canonical channels are essential for chemotactic migration of human malignant gliomas. J. Cell. Physiol. 2011, 226:1879-1888.
150. Tajeddine N., Gailly P. TRPC1 protein channel is major regulator of epidermal growth factor receptor signaling. J. Biol. Chem. 2012, 287:16146-16157.
151. Jiang H.N., Zeng B., Zhang Y., Daskoulidou N., Fan H., Qu J.M., Xu S.Z. Involvement of TRPC channels in lung cancer cell differentiation and the correlation analysis in human non-small cell lung cancer. PLoS One 2013, 8:e67637.
152. He B., Liu F., Ruan J., Li A., Chen J., Li R., Shen J., Zheng D., Luo R. Silencing TRPC1 expression inhibits invasion of CNE2 nasopharyngeal tumor cells. Oncol. Rep. 2012, 27:1548-1554.
153. Zeng B., Yuan C., Yang X., Atkin S.L., Xu S.Z. TRPC channels and their splice variants are essential for promoting human ovarian cancer cell proliferation and tumorigenesis. Curr. Cancer Drug Targets 2013, 13:103-116.
154. Yang S., Zhang J.J., Huang X.Y. Orai1 and STIM1 are critical for breast tumor cell migration and metastasis. Cancer Cell 2009, 15:124-134.
155. Chantôme A., Potier-Cartereau M., Clarysse L., Fromont G., Marionneau-Lambot S., Guéguinou M., Pagès J.C., Collin C., Oullier T., Girault A., Arbion F., Haelters J.P., Jaffrès P.A., Pinault M., Besson P., Joulin V., Bougnoux P., Vandier C. Pivotal role of the lipid Raft SK3-Orai1 complex in human cancer cell migration and bone metastases. Cancer Res. 2013, 73:4852-4861.
156. Porta C., Paglino C., Imarisio I., Ganini C., Sacchi L., Quaglini S., Giunta V., De Amici M. Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients. Oncology 2013, 84:115-122.
157. Dragoni S., Guerra G., Fiorio Pla A., Bertoni G., Rappa A., Poletto V., Bottino C., Aronica A., Lodola F., Cinelli M.P., Laforenza U., Rosti V., Tanzi F., Munaron L., Moccia F. A functional Transient Receptor Potential Vanilloid 4 (TRPV4) channel is expressed in human endothelial progenitor cells. J. Cell. Physiol. 2015, 230:95-104.
158. 2+ influx and cytokine production by facilitating transient receptor potential melastatin 4 channel activity. Mol. Pharmacol. 2006, 69:1413-1420.
159. Beech D.J. Orai1 calcium channels in the vasculature. Pflugers Arch. 2012, 463:635-647.
160. 2+ entry pathways. Br. J. Pharmacol. 2012, 167:1712-1722.
161. + T cells. EMBO Mol. Med. 2013, 5:1311-1321.
162. Jin S., Chin J., Kitson C., Woods J., Majmudar R., Carvajal V., Allard J., Demartino J., Narula S., Thomas-Karyat D.A. Natural regulatory T cells are resistant to calcium release-activated calcium (CRAC/ORAI) channel inhibition. Int. Immunol. 2013, 25:497-506.
163. Whiteside T.L., Schuler P., Schilling B. Induced and natural regulatory T cells in human cancer. Expert. Opin. Biol. Ther. 2012, 12:1383-1397.
164. 2+ entry does not control proliferation in primary cultures of human metastatic renal cellular carcinoma. Biomed. Res. Int. 2014, 2014:739494.
165. Korosec B., Glavac D., Rott T., Ravnik-Glavac M. Alterations in the ATP2A2 gene in correlation with colon and lung cancer. Cancer Genet. Cytogenet. 2006, 171:105-111.
166. Korosec B., Glavac D., Volavsek M., Ravnik-Glavac M. ATP2A3 gene is involved in cancer susceptibility. Cancer Genet. Cytogenet. 2009, 188:88-94.
167. 2+ pumps in association with head and neck squamous cell carcinoma. Cancer Genet. Cytogenet. 2008, 181:112-118.
168. Mareel M., Oliveira M.J., Madani I. Cancer invasion and metastasis: interacting ecosystems. Virchows Arch. 2009, 454:599-622.
169. Zhuang G., Wu X., Jiang Z., Kasman I., Yao J., Guan Y., Oeh J., Modrusan Z., Bais C., Sampath D., Ferrara N. Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J. 2012, 31:3513-3523.
170. Grange C., Tapparo M., Collino F., Vitillo L., Damasco C., Deregibus M.C., Tetta C., Bussolati B., Camussi G. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res. 2011, 71:5346-5356.
171. Hong B.S., Cho J.H., Kim H., Choi E.J., Rho S., Kim J., Kim J.H., Choi D.S., Kim Y.K., Hwang D., Gho Y.S. Colorectal cancer cell-derived microvesicles are enriched in cell cycle-related mRNAs that promote proliferation of endothelial cells. BMC Genomics 2009, 10:556.
172. Bussolati B., Grange C., Camussi G. Tumor exploits alternative strategies to achieve vascularization. FASEB J. 2011, 25:2874-2882.
173. Hellebrekers D.M., Melotte V., Viré E., Langenkamp E., Molema G., Fuks F., Herman J.G., Van Criekinge W., Griffioen A.W., van Engeland M. Identification of epigenetically silenced genes in tumor endothelial cells. Cancer Res. 2007, 67:4138-4148.
174. Hellebrekers D.M., Castermans K., Viré E., Dings R.P., Hoebers N.T., Mayo K.H., Oude Egbrink M.G., Molema G., Fuks F., van Engeland M., Griffioen A.W. Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications. Cancer Res. 2006, 66:10770-10777.
175. Hellebrekers D.M., Griffioen A.W., van Engeland M. Dual targeting of epigenetic therapy in cancer. Biochim. Biophys. Acta 2007, 1775:76-91.
176. 2+. Stem Cells Dev. 2012, 21:1418-1428.
177. Ma X., Cai Y., He D., Zou C., Zhang P., Lo C.Y., Xu Z., Chan F.L., Yu S., Chen Y., Zhu R., Lei J., Jin J., Yao X. Transient receptor potential channel TRPC5 is essential for P-glycoprotein induction in drug-resistant cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:16282-16287.
178. Ma X., Chen Z., Hua D., He D., Wang L., Zhang P., Wang J., Cai Y., Gao C., Zhang X., Zhang F., Wang T., Hong T., Jin L., Qi X., Chen S., Gu X., Yang D., Pan Q., Zhu Y., Chen Y., Chen D., Jiang L., Han X., Zhang Y., Jin J., Yao X. Essential role for TrpC5-containing extracellular vesicles in breast cancer with chemotherapeutic resistance. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:6389-6394.
179. Peinado H., Lavotshkin S., Lyden D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin. Cancer Biol. 2011, 21:139-146.
180. Peinado H., Alečković M., Lavotshkin S., Matei I., Costa-Silva B., Moreno-Bueno G., Hergueta-Redondo M., Williams C., García-Santos G., Ghajar C., Nitadori-Hoshino A., Hoffman C., Badal K., Garcia B.A., Callahan M.K., Yuan J., Martins V.R., Skog J., Kaplan R.N., Brady M.S., Wolchok J.D., Chapman P.B., Kang Y., Bromberg J., Lyden D. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 2012, 18:883-891.
181. Asahara T., Takahashi T., Masuda H., Kalka C., Chen D., Iwaguro H., Inai Y., Silver M., Isner J.M. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999, 18:3964-3972.
182. Davidoff A.M., Ng C.Y., Brown P., Leary M.A., Spurbeck W.W., Zhou J., Horwitz E., Vanin E.F., Nienhuis A.W. Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice. Clin. Cancer Res. 2001, 7:2870-2879.
183. Reyes M., Dudek A., Jahagirdar B., Koodie L., Marker P.H., Verfaillie C.M. Origin of endothelial progenitors in human postnatal bone marrow. J. Clin. Invest. 2002, 109:337-346.
184. De Palma M., Venneri M.A., Roca C., Naldini L. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat. Med. 2003, 9:789-795.
185. Garcia-Barros M., Paris F., Cordon-Cardo C., Lyden D., Rafii S., Haimovitz-Friedman A., Fuks Z., Kolesnick R. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003, 300:1155-1159.
186. Dwenger A., Rosenthal F., Machein M., Waller C., Spyridonidis A. Transplanted bone marrow cells preferentially home to the vessels of in situ generated murine tumors rather than of normal organs. Stem Cells 2004, 22:86-92.
187. Rajantie I., Ilmonen M., Alminaite A., Ozerdem U., Alitalo K., Salven P. Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood 2004, 104:2084-2086.
188. Göthert J.R., Gustin S.E., van Eekelen J.A., Schmidt U., Hall M.A., Jane S.M., Green A.R., Göttgens B., Izon D.J., Begley C.G. Genetically tagging endothelial cells in vivo: bone marrow-derived cells do not contribute to tumor endothelium. Blood 2004, 104:1769-1777.
189. Spring H., Schüler T., Arnold B., Hämmerling G.J., Ganss R. Chemokines direct endothelial progenitors into tumor neovessels. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:18111-18116.
190. Duda D.G., Cohen K.S., Kozin S.V., Perentes J.Y., Fukumura D., Scadden D.T., Jain R.K. Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors. Blood 2006, 107:2774-2776.
191. Purhonen S., Palm J., Rossi D., Kaskenpää N., Rajantie I., Ylä-Herttuala S., Alitalo K., Weissman I.L., Salven P. Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:6620-6625.
192. Jung S.Y., Choi J.H., Kwon S.M., Masuda H., Asahara T., Lee Y.M. Decursin inhibits vasculogenesis in early tumor progression by suppression of endothelial progenitor cell differentiation and function. J. Cell. Biochem. 2012, 113:1478-1487.
193. Zhang H.R., Chen F.L., Xu C.P., Ping Y.F., Wang Q.L., Liang Z.Q., Wang J.M., Bian X.W. Incorporation of endothelial progenitor cells into the neovasculature of malignant glioma xenograft. J. Neurooncol. 2009, 93:165-174.